Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A synthetic deoxyribonuclease obtained by human recombinant technology (rhDNase). A protein structure formed by 260 amino acids. It behaves like an enzyme that hydrolyzes DNA in mucus. Indicated as a mucolytic in patients with cystic fibrosis.
Administration via inhalation once to twice a day.
Since the last update we have not found published data on its excretion in breastmilk.
Systemic absorption is very low and there is no accumulation. DNase is normally present in human serum. Endogenous plasma levels of DNase were not significantly modified after inhalation treatment over several months (FDA 2018, AEMPS 2015).
Its very high molecular weight makes it very unlikely it will transfer into breastmilk in significant amounts (AEMPS 2015).
Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed (practically zero oral bioavailability), which hinders transfer to infant plasma from breastmilk.